Cocrystal Pharma, Inc. COCP 深 滬
等待開盤 09-11 09:30:00 美东时间
1.46
+0.010
+0.69%
華盛通- 最 高1.48
- 今 開1.43
- 成交量 5.27万股
- 最 低 1.43
- 昨 收 1.45
- 總市值 1485.37万
- 52周最高 3.26
- 市盈率 靜 --
- 換手率 0.52%
- 52周最低 1.12
- 委 比 -13.42%
- 總股本 1017.38万
- 歷史最高 66.00
- 量 比 0.70
- 振 幅 3.45%
- 歷史最低 1.12
- 每 手 1
- 風險率 0.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cocrystal Pharma Receives Study May Proceed Letter From FDA To Conduct Phase 1b Challenge Study Evaluating CDI-988 For Prevention And Treatment Of Norovirus Infections; Phase 1b Challenge Study Is Planned To Begin Before Year-End 2025
There are currently no approved vaccines or treatments for norovirus infectionCocrystal's CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused by norovirus
09-08 20:01
Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment
Cocrystal Pharma received FDA approval for a Phase 1b study of CDI-988, a novel oral antiviral targeting norovirus infections. With no approved vaccines or treatments for norovirus, CDI-988 is the first potential option for its prevention and treatment. The study is set to begin by late 2025. CDI-988 has shown broad-spectrum activity against key norovirus strains and demonstrated a favorable safety profile in Phase 1 trials. Norovirus is a leadin...
09-08 12:00
Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference
Cocrystal Pharma, Inc. announced that its CFO and co-CEO, James Martin, will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 12:00 p.m. Eastern time. Mr. Martin will be available for in-person and virtual one-on-one meetings. Investors and professionals can register to attend virtually or in-person at the Lotte New York Palace Hotel. Cocrystal Pharma, a clinical-stage biotechnolo...
09-03 12:00
Cocrystal Pharma Q2 EPS $(0.20) Beats $(0.30) Estimate
Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.30) by 33.33 percent. This is a 62.26 percent increase over losses of $(0.53) per share from
08-14 20:13
Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Cocrystal Pharma reports positive safety and tolerability results for CDI-988 in Phase 1 trials, with plans for a human challenge study later this year to evaluate its effectiveness against norovirus. Both CDI-988 and CC-42344 are advancing in clinical trials, targeting norovirus and coronaviruses, influenza A, and other viral threats. The company also provided financial updates, including reduced R&D expenses and a net loss, while cash reserves ...
08-14 12:00
Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference
Cocrystal Pharma's CDI-988, an oral pan-viral protease inhibitor, demonstrated favorable safety and tolerability in a Phase 1 study across doses of 100 mg to 1200 mg. The company plans to initiate a Phase 1b study in norovirus-infected subjects later this year. Norovirus currently has no approved treatments or vaccines, creating a critical unmet medical need. CDI-988 targets viral replication and could offer broad-spectrum protection against noro...
08-05 12:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 4D Molecular Therapeutics (NASDAQ:FDMT) shares moved upwards by 33.1% ...
08-01 05:07
Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference
Cocrystal Pharma's first-in-class pan-viral protease inhibitor CDI-988, targeting norovirus and coronaviruses, will be presented at the 9th International Calicivirus Conference in September. The company highlights CDI-988's potential as an oral treatment against all norovirus strains, including GII.4 and GII.17. Phase 1 results and clinical strategy will be discussed by Dr. Sam Lee. CDI-988, developed using Cocrystal's structure-based platform, s...
07-10 12:00
美股大行评级 | 潜在涨幅378.93%！aTyr Pharma获富国银行升目标价至25美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1143101010774646784.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 富国银行：维持aTyr Pharma(ATYR)"超配"评级，目标价从17美元升至25美元</p> <p>• 摩根大通：维持Array Technologies(ARRY)"超配"评级，目标价从12美元升至13美元</p>
06-21 08:35
HC Wainwright & Co. Maintains Buy on Cocrystal Pharma, Lowers Price Target to $6
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cocrystal Pharma (NASDAQ:COCP) with a Buy and lowers the price target from $7 to $6.
06-20 19:16
